Study 2: baseline patient characteristics separated by whether patients were or were not taking an ACE-I or ARB.
| ARB or ACE-I n=130 | No ARB or ACE-I n=243 | p Value | |
|---|---|---|---|
| Age (years) | 71 (64, 78) | 67.6 (9.8) | 0.004 |
| FEV1 (% predicted) | 44.5 (32.3, 60.8) | 39.0 (26.0, 58.5) | 0.007 |
| FFM (kg) | 51.1 (11.2) | 45.5 (40.1, 52.0) | <0.001 |
| FFMI (kg/m2) | 17.8 (16.0, 19.8) | 16.5 (14.9, 18.4) | <0.001 |
| ISWD (m) | 140 (60, 250) | 160 (80, 280) | 0.10 |
| CRQ | 71.5 (55.8, 91.0) | 68.0 (56.0, 87.0) | 0.45 |
| MRC dyspnoea score | 4 (3, 5) | 4 (3, 5) | 0.79 |
| CAT score | 23.0 (8.0) | 22.0 (7.0) | 0.76 |
p Values are for unpaired t-tests. Data are presented as median (25th, 75th centiles) or (SD).
ACE-I, ACE inhibitor; ARB, AT II receptor antagonist; CAT, COPD assessment test score; CRQ, chronic respiratory disease questionnaire; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; FFM, fat free mass; FFMI, fat free mass index; ISWD, incremental shuttle walk test distance.